The Feds’ Position On Medical Pot: Organic = Bad, Organix = Good; Any Questions?
Marijuana chemical may slow multiple sclerosis
Armed with a $1.5 million National Institutes of Health grant, Temple researchers are studying more effective ways to treat multiple sclerosis. And their research utilizes synthetic cannabinoids based on chemicals derived from the marijuana plant.
… Using a compound (O-1996) synthesized by scientists at the Medical College of Virginia and the company Organix, Tuma and Ganea performed animal studies and found that the synthesized chemical affected cannabinoid receptors present primarily on immune cells.
… “This is a totally new approach to treating this disease, “says Adler, director emeritus and senior advisor for CSAR and Laura H. Carnell professor of pharmacology research. “These cannabinoids hold enormous potential, and that’s encouraging since we’re limited in options when it comes to preventing or reversing MS.”
Okay, follow along with me if you can.
The U.S. National Institutes of Health appropriates over one million dollars to fund medical research — not to investigate the therapeutic effects of natural cannabinoids (bad!), but rather to investigate the therapeutic effects of synthetic chemicals (good!) that are designed to mimic the effects of natural cannabinoids.
Equally ironically, the research is taking place at Temple University in Pennsylvania — where any use of natural cannabis (bad!) as a medicine is criminally illegal, but where research into the use faux cannabis (good!) is embraced.
Makes sense, right? Well about as much sense as the federal government claiming that pot (bad!) has no medical utility while simultaneously patenting certain natural occurring chemicals in the plant — those that the Feds hope to one day profit from (good!) — as, you guessed it, a medicine.
Any questions? June 2, 2009